Rocket Pharma Q1 net loss narrows to $47.6 million; R&D expenses fall to $31.5 million

• Rocket Pharmaceuticals posted a first-quarter net loss of $47.6 million, or $0.42 a share, narrowing from a $61.3 million loss, or $0.56 a share, a year earlier.
• R&D expense fell 12.26% to $31.5 million, driven by lower manufacturing and development and direct material costs, partially offset by higher clinical trial spending.
• G&A expense dropped 39.79% to $17.1 million on lower legal and commercial preparation-related costs, partly offset by higher milestone-related expenses.
• Cash, cash equivalents and investments totaled $144.4 million at March 31, excluding Priority Review Voucher monetization; pro forma cash was about $322.6 million following the $180 million PRV sale, extending expected runway into second-quarter 2028.
• Dosing restarted in the pivotal Phase 2 RP-A501 Danon disease trial with three additional patients at 3.8 × 10¹³ GC/kg; first patient dosing in Phase 1 RP-A701 for BAG3-related dilated cardiomyopathy expected in mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605071600BIZWIRE_USPR_____20260507_BW193942) on May 07, 2026, and is solely responsible for the information contained therein.